Myrexis CEO Richard Brewer dies
This article was originally published in Scrip
Richard Brewer, CEO of Myrexis since May 2012, has died after a long battle with multiple myeloma. His colleague, Myrexis' COO David Gryska, will become acting CEO until the company communicates its succession plans in the coming weeks. He said of Mr Brewer, "Dick was a one-of-a-kind trailblazer and visionary who made an indelible mark on the biotech industry and on the lives of the many colleagues he inspired and influenced, family and friends he loved and enjoyed, and patients who benefited from his risk-taking work and advocacy."
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.